Immunotherapy is currently not an effective treatment for ovarian cancer, but our results suggested that low-risk patients may have the opportunity to respond to certain immunotherapy such as immune checkpoint inhibitors targeting CTLA4. The gene discussed is CTLA4; the disease is ovarian cancer.